Ephemeranthol A
Ephemeranthol A is a phenanthrene compound with anticancer and anti-inflammatory activities. Ephemeranthol A exerts significant anti-inflammatory effects in macrophages by inhibiting the NF-κB and MAPK signaling pathways. Ephemeranthol A induces apoptosis and inhibits metastasis of lung cancer cells by suppressing the FAK/Akt signaling and EMT processes. Ephemeranthol A can be used for the research of acute and chronic inflammatory diseases and non-small cell lung cancer.
For research use only. We do not sell to patients.
- CAS No.: 135545-86-7
- Formula: C16H16O4
- Molecular Weight:272.30
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
IC50 & Target
[1]|
NF-κB |
iNOS |
COX-2 |
IL-1β |
IL-6 |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| A549 | IC50 |
10 μM
Compound: 7
|
Cytotoxicity against human A549 cells assessed as decrease in cell viability after 6 days by MTT assay
Cytotoxicity against human A549 cells assessed as decrease in cell viability after 6 days by MTT assay
|
[PMID: 27310249] |
In Vitro
Ephemeranthol A (6.25-50 μg/mL; 25 h) shows no cytotoxicity against Raw 264.7 cells at concentrations ≤ 25 μg/mL, but reduces cell viability at 50 μg/mL[1].
Ephemeranthol A (6.25-50 μg/mL; 7-25 h) potently inhibits LPS-induced production of NO, iNOS, COX-2, TNF-α, IL-6 and IL-1β in Raw 264.7 cells[1].
Ephemeranthol A (25 μg/mL; 1.5-2 h) blocks LPS-induced IκB degradation and inhibits the nuclear translocation of NF-κB subunits p50 and p65 in Raw 264.7 cells [1].
Ephemeranthol A (6.25-25 μg/mL; 1 h) inhibits LPS-induced phosphorylation of p38 and JNK in Raw 264.7 cells[1].
Ephemeranthol A (5-200 μM; 24-48 h) reduces the viability of human non-small cell lung cancer H460 cells in a concentration- and time-dependent manner, with an IC50 > 200 μM at 24 h and an IC50 of 150.5 μM at 48 h[2].
Ephemeranthol A (10-100 μM; 24 h) induces apoptosis in human non-small cell lung cancer H460 cells in a concentration-dependent manner[2].
Ephemeranthol A (50-100 μM; 48 h) induces apoptosis in human non-small cell lung cancer H460 cells at 48 h by decreasing Bcl-2 levels and activating caspase-9, caspase-3 and PARP[2].
Ephemeranthol A (50-100 μM; 48 h) inhibits the activation of the FAK-Akt signaling pathway in human non-small cell lung cancer H460 cells at 48 h[2].
Ephemeranthol A (5-50 μM; 48 h) inhibits anchorage-independent growth of human non-small cell lung cancer H460 cells[2].
Ephemeranthol A (10-100 μM; 24-48 h) inhibits migration of human non-small cell lung cancer H460 cells[2].
Ephemeranthol A (5-100 μM; 24-48 h) inhibits epithelial-mesenchymal transition and induces epithelial morphological changes in human non-small cell lung cancer H460 cells[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:Raw 264.7 murine macrophage cells
-
Concentration:25 μg/mL
-
Incubation Time:1 h pre-incubation; 6 h LPS stimulation
-
Result:Reduced LPS-induced iNOS protein production in Raw 264.7 cells.\n
Reduced LPS-induced COX-2 protein production in Raw 264.7 cells.
-
Cell Line:Raw 264.7 murine macrophage cells
-
Concentration:25 μg/mL
-
Incubation Time:1 h pre-incubation; 6 h LPS stimulation
-
Result:Significantly decreased LPS-induced mRNA levels of TNF-α, IL-6, and IL-1β.
Reduced TNF-α and IL-6 mRNA levels to the level of the unstimulated control.
-
Cell Line:Raw 264.7 murine macrophage cells
-
Concentration:25 μg/mL
-
Incubation Time:1 h pre-incubation; 24 h LPS stimulation
-
Result:Significantly inhibited LPS-induced production of TNF-α, IL-6, and IL-1β protein in Raw 264.7 cells.
-
Cell Line:Raw 264.7 murine macrophage cells
-
Concentration:25 μg/mL
-
Incubation Time:1 h pre-incubation; 30 min or 1 h LPS stimulation
-
Result:Blocked LPS-induced IκB degradation at 30 min post-stimulation.
Sustained the inhibitory effect until 1 h post-stimulation.\n
Inhibited LPS-induced translocation of p50 and p65 into the nucleus at 30 min post-stimulation.
-
Cell Line:Raw 264.7 murine macrophage cells
-
Concentration:25 μg/mL (p38, JNK phosphorylation at 10/20 min); 6.25, 12.5 and 25 μg/mL (p38 phosphorylation at 10 min)
-
Incubation Time:1 h pre-incubation; 10 min or 20 min LPS stimulation (p38, JNK phosphorylation); 1 h pre-incubation, 10 min LPS stimulation (p38 phosphorylation dose-response)
-
Result:Reduced LPS-induced phosphorylation of p38 and JNK at 10 min and 20 min post-stimulation.
Sustained the inhibitory effect on JNK phosphorylation for 20 min.
Induced a dose-dependent reduction in LPS-induced p38 phosphorylation at 6.25, 12.5, and 25 μg/mL.
-
Cell Line:human non-small cell lung cancer H460 cells
-
Concentration:5, 10, 50, 100 and 200 μM
-
Incubation Time:24 h; 48 h
-
Result:Exhibited non-toxic to slightly toxic effects at concentrations ≤ 50 μM.
Caused significant cell viability reduction at 100 and 200 μM at both 24 and 48 h.
Reached an IC50 of > 200 μM at 24 h and 150.5 μM at 48 h.
-
Cell Line:human non-small cell lung cancer H460 cells
-
Concentration:10, 50 and 100 μM
-
Incubation Time:24 h
-
Result:Induced concentration-dependent increases in apoptotic cell number.
Resulted in a significant increase to ~17% apoptotic nuclei at 100 μM.
Kept necrotic cell numbers minimal across all concentrations.
-
Cell Line:human non-small cell lung cancer H460 cells
-
Concentration:50, 100 μM
-
Incubation Time:48 h
-
Result:Increased cleaved PARP levels 1.98-fold (50 μM) and 2.33-fold (100 μM).
Increased cleaved caspase-9 levels 1.52-fold (50 μM) and 1.73-fold (100 μM).
Increased cleaved caspase-3 levels 4.78-fold (100 μM).
Reduced Bcl-2 levels to 0.63-fold (100 μM).
Showed no significant effects on Mcl-1 or Bax levels.
Reduced the p-FAK/total FAK ratio to 0.82-fold (50 μM) and 0.59-fold (100 μM).
Reduced the p-Akt/total Akt ratio to 0.52-fold (100 μM).
Kept total FAK and total Akt levels largely unchanged.
-
Cell Line:human non-small cell lung cancer H460 cells
-
Concentration:10, 50 and 100 μM
-
Incubation Time:24 h; 48 h
-
Result:Showed no significant effect on wound closure at 24 h.
Reduced wound closure to 33.77% (50 μM) and 25.06% (100 μM) at 48 h, compared to untreated control wound closure of 38.40%.
Chemical Information
-
CAS No. 135545-86-7
-
Molecular Weight 272.30
-
Formula C16H16O4
-
SMILES
OC1=CC2=C(C3=C(C(OC)=C(C=C3CC2)OC)O)C=C1
-
Structure Classification
-
Initial Source
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
-
Orthotopic Cell-Line Xenograft
Orthotopic cell-line xenograft models involve implantation of human cancer cell lines into the anatomically corresponding organ of immunodeficient mice to reproduce tumor growth within a native microenvironment, enabling more clinically relevant tumor behavior compared with subcutaneous models. These models are widely used because orthotopic placement better recapitulates tumor progression, including invasion and metastatic spread, which are often underrepresented in heterotopic implantation systems. Compared with conventional xenografts, orthotopic implantation is described as more technically complex but provides improved simulation of tumor-microenvironment interactions and metastatic behavior, making it particularly valuable for translational oncology research. Surgical orthotopic implantation approaches have been emphasized as enabling faithful reproduction of clinical cancer features, including metastasis and disease progression patterns that align with the tumor’s organ of origi
Purity & Documentation
References
[1]. Kim JH, et al. Anti-inflammatory effects of Dendrobium nobile derived phenanthrenes in LPS-stimulated murine macrophages. Arch Pharm Res. 2015;38(6):1117-1126. [Content Brief]
[2]. Nonpanya N, et al. Ephemeranthol A Suppresses Epithelial to Mesenchymal Transition and FAK-Akt Signaling in Lung Cancer Cells. Anticancer Res. 2020;40(9):4989-4999. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)